David Lebowitz
Stock Analyst at Citigroup
(4.32)
# 347
Out of 5,090 analysts
119
Total ratings
59.77%
Success rate
14.28%
Average return
Main Sectors:
Stocks Rated by David Lebowitz
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IONS Ionis Pharmaceuticals | Maintains: Buy | $69 → $84 | $81.68 | +2.84% | 14 | Sep 3, 2025 | |
| CYTK Cytokinetics | Maintains: Buy | $77 → $84 | $65.67 | +27.91% | 4 | Sep 2, 2025 | |
| CLDX Celldex Therapeutics | Maintains: Buy | $56 → $48 | $29.45 | +62.99% | 2 | Aug 20, 2025 | |
| SDGR Schrödinger | Downgrades: Neutral | $35 → $20 | $17.64 | +13.38% | 10 | Aug 15, 2025 | |
| ASND Ascendis Pharma | Maintains: Buy | $243 → $290 | $205.44 | +41.16% | 14 | Aug 8, 2025 | |
| INCY Incyte | Maintains: Buy | $88 → $103 | $102.52 | +0.47% | 6 | Jul 30, 2025 | |
| VKTX Viking Therapeutics | Maintains: Neutral | $31 → $38 | $38.55 | -1.43% | 2 | Jul 24, 2025 | |
| COGT Cogent Biosciences | Maintains: Buy | $15 → $22 | $38.77 | -43.26% | 4 | Jul 18, 2025 | |
| BBIO BridgeBio Pharma | Maintains: Buy | $58 → $67 | $73.64 | -9.02% | 5 | Jul 11, 2025 | |
| EXEL Exelixis | Maintains: Buy | $45 → $56 | $44.36 | +26.24% | 3 | May 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $14 → $10 | $9.61 | +4.06% | 8 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $4 → $1.5 | $1.21 | +23.97% | 6 | Mar 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $32 → $45 | $77.26 | -41.75% | 4 | Feb 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $65 → $68 | $68.48 | -0.70% | 4 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $382 | $577.30 | -33.83% | 1 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $103 → $96 | $53.40 | +79.78% | 3 | Jun 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $18 → $12 | $6.40 | +87.50% | 2 | Jul 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $170 → $164 | $458.12 | -64.20% | 7 | Jul 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $36 → $39 | $31.20 | +25.00% | 6 | Jun 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $20 → $21 | $20.32 | +3.35% | 11 | Oct 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $435 → $405 | $5.75 | +6,943.48% | 1 | Oct 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $13 → $14 | $3.48 | +302.30% | 2 | Oct 12, 2021 |
Ionis Pharmaceuticals
Sep 3, 2025
Maintains: Buy
Price Target: $69 → $84
Current: $81.68
Upside: +2.84%
Cytokinetics
Sep 2, 2025
Maintains: Buy
Price Target: $77 → $84
Current: $65.67
Upside: +27.91%
Celldex Therapeutics
Aug 20, 2025
Maintains: Buy
Price Target: $56 → $48
Current: $29.45
Upside: +62.99%
Schrödinger
Aug 15, 2025
Downgrades: Neutral
Price Target: $35 → $20
Current: $17.64
Upside: +13.38%
Ascendis Pharma
Aug 8, 2025
Maintains: Buy
Price Target: $243 → $290
Current: $205.44
Upside: +41.16%
Incyte
Jul 30, 2025
Maintains: Buy
Price Target: $88 → $103
Current: $102.52
Upside: +0.47%
Viking Therapeutics
Jul 24, 2025
Maintains: Neutral
Price Target: $31 → $38
Current: $38.55
Upside: -1.43%
Cogent Biosciences
Jul 18, 2025
Maintains: Buy
Price Target: $15 → $22
Current: $38.77
Upside: -43.26%
BridgeBio Pharma
Jul 11, 2025
Maintains: Buy
Price Target: $58 → $67
Current: $73.64
Upside: -9.02%
Exelixis
May 15, 2025
Maintains: Buy
Price Target: $45 → $56
Current: $44.36
Upside: +26.24%
May 9, 2025
Maintains: Neutral
Price Target: $14 → $10
Current: $9.61
Upside: +4.06%
Mar 4, 2025
Maintains: Neutral
Price Target: $4 → $1.5
Current: $1.21
Upside: +23.97%
Feb 12, 2025
Maintains: Sell
Price Target: $32 → $45
Current: $77.26
Upside: -41.75%
Nov 13, 2024
Maintains: Buy
Price Target: $65 → $68
Current: $68.48
Upside: -0.70%
Mar 6, 2024
Initiates: Buy
Price Target: $382
Current: $577.30
Upside: -33.83%
Jun 30, 2023
Maintains: Neutral
Price Target: $103 → $96
Current: $53.40
Upside: +79.78%
Jul 15, 2022
Maintains: Equal-Weight
Price Target: $18 → $12
Current: $6.40
Upside: +87.50%
Jul 15, 2022
Maintains: Equal-Weight
Price Target: $170 → $164
Current: $458.12
Upside: -64.20%
Jun 7, 2022
Maintains: Overweight
Price Target: $36 → $39
Current: $31.20
Upside: +25.00%
Oct 12, 2021
Maintains: Equal-Weight
Price Target: $20 → $21
Current: $20.32
Upside: +3.35%
Oct 12, 2021
Maintains: Overweight
Price Target: $435 → $405
Current: $5.75
Upside: +6,943.48%
Oct 12, 2021
Maintains: Equal-Weight
Price Target: $13 → $14
Current: $3.48
Upside: +302.30%